After adjustment for gender, age, pathological stage, vascular invasion, lymphatic permeation, GORASP2 expression, ZYG11A expression, and SFN expression, patients with strong expression of GORASP2 and ZYG11A showed a significantly higher risk of lung cancer-related death than those with weak expression {(HR: 0.332, 95% CI: 0.179–0.613, P: < 0.001) and (HR: 0.286, 95% CI: 0.155–0.527, P: < 0.001)}. The gene discussed is GORASP2; the disease is lung carcinoma.